

IN THE CLAIMS

1-26. (canceled)

27. (currently amended) An *in vitro* method of treating a neoplastic cell, comprising:
administering to the cell a therapeutically effective amount of antisense oligonucleotides which are complementary to: an mRNA comprising ~~nucleotides 312-1784~~ of SEQ ID NO:2 and encoding human MDM2, and which inhibit expression of human MDM2 protein.

28-55. (canceled)

56. (currently amended) An *in vitro* method of treating a cell having an amplified human MDM2 gene, elevated expression of human MDM2 mRNA, or elevated expression of human MDM2 protein, comprising:

administering to the cell a therapeutically effective amount of antisense oligonucleotides which are complementary to an mRNA comprising ~~nucleotides 312-1784~~ of SEQ ID NO:2 and encoding human MDM2 and which inhibit expression of human MDM2 protein.

57-61. (canceled)

62. (currently amended) An *in vitro* method of interfering with expression of human MDM2 protein, comprising administering to a neoplastic cell an antisense oligonucleotide which is complementary to: an mRNA comprising ~~nucleotides 312-1784~~ of SEQ ID NO:2 and encoding human MDM2, in an amount effective to interfere with expression of human MDM2 protein.

63. (currently amended) An *in vitro* method of interfering with expression of human MDM2 protein, comprising:

administering to a cell having an amplified human MDM2 gene, elevated expression of human MDM2 mRNA, or elevated expression of human MDM2 protein an antisense oligonucleotide which is complementary to: an mRNA comprising ~~nucleotides 312-1784~~ of SEQ ID NO:2 and encoding human MDM2, in an amount effective to interfere with expression of human MDM2.

64-67. (canceled)